EGFR and neoplasm: It has been demonstrated that epigenetic modifications, genetic abnormalities, and alterations in cell signaling pathways, specifically those involving the p53 tumor suppressor gene, epidermal growth factor receptor (EGFR), and the PI3K/AKT/mTOR axis, drive tumor development and progression [7,8].